Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) posted its earnings results on Tuesday. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.20), FiscalAI reports. The company had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS.

Kiniksa Pharmaceuticals International Trading Down 0.8%

Kiniksa Pharmaceuticals International stock opened at $47.39 on Tuesday. Kiniksa Pharmaceuticals International has a 52 week low of $18.25 and a 52 week high of $49.12. The stock has a market cap of $3.59 billion, a P/E ratio of 105.31 and a beta of 0.06. The stock has a 50 day moving average of $42.83 and a 200-day moving average of $39.56.

Insider Activity

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,048 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the transaction, the chief operating officer owned 16,666 shares of the company’s stock, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 123,823 shares of company stock worth $5,244,967. 53.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd grew its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after buying an additional 447,536 shares during the period. Nomura Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $15,421,000. Finally, Logos Global Management LP bought a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $14,438,000. Institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KNSA. The Goldman Sachs Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.71.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.